Гепаторенальный синдром


*

Представлены этиология, особенности патогенеза, подходы к диагностике и лечению гепаторенального синдрома.

Литература


1. Wadei H.M., Mai M.L., Ahsan N. et al. Hepatorenal syndrome: pathophysiology and management. Clin. J. Am. Soc. Nephrol. 2006; 1: 1066–1079.
2. Moreau R., Durand F., Poynard T. et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 2002; 122: 923–930.
3. Wong L.P., Blackley M.P., Andreoni K.A. et al. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int. 2005; 68: 362–370 .
4. Schepke M., Appenrodt B., Heller J. et al. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int. 2006; 26: 834–839.
5. Turban S., Thuluvath P.J., Atta M.G. Hepatorenal syndrome. World. J. Gastroenterol. 2007; 13(30): 4046–4055.
6. Ruiz-del-Arbol L., Monescillo A., Arocena C. et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439–447.
7. Sort P., Navasa M., Arroyo V. et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N. Engl. J. Med. 1999; 341: 403–409.
8. Gines P., Tito L., Arroyo V. et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493–1502.
9. Akriviadis E., Botla R., Briggs W. et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637–1648.
10. Cardenas A., Gines P., Uriz J. et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and shortterm prognosis. Hepatology 2001; 34: 671–676.
11. Gines P., Guevara M., Arroyo V. et al. Hepatorenal syndrome. Lancet 2003; 362: 1819–1827.
12. Gines A, Escorsell A, Gines P. et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229–236.
13. Platt J.F., Ellis J.H., Rubin J.M. et al. Renal duplex Doppler ultrasonography: A noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 1994; 20: 362–369.
14. Lee S., Son S.C., Han M.J. et al. Increased intestinal molecular permeability and urine nitrite excretion associated with liver cirrhosis with ascites. World. J. Gastroenterol. 2008; 14(24): 3884–3890.
15. Ancel D. Barraud H., Peyrin-Biroulet L. et al. Intestinal permeability and cirrhosis. Gastroenterol. Clin. Biol. 2006; 30(3): 460–468.
16. Kiki I., Yilmaz O., Erdem F. et al. Tumour necrosis factor-alpha levels in hepatitis B virus-related chronic active hepatitis and liver cirrhosis and its relationship to Knodell and Child-Pugh scores. Int. J. Clin. Pract. 2006; 60(9): 1075–1079.
17. Tiegs G. Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury. Z. Gastronterol. 2007; 45(1): 63–70.
18. Martin P.Y., Gines P., Schrier R.W. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533–541.
19. Epstein M., Goligorsky M. Endothelin and nitric oxide in hepatorenal syndrome: a balance reset. J. Nephrol. 1997; 10(3): 120–135.
20. Grange J.D., Amiot X. Nitric oxide and renal function in cirrhotic patients with ascites: from physiopathology to practice. Eur. J. Gastroenterol. Hepatol. 2004; 16(6): 567–570.
21. Laffi G., Foschi M., Masini E. et al. Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. Hepatology 1995; 22: 1666–1673.
22. Mitchell J.A., Kohlhaas K.L., Sorrentino R. et al. Induction by endotoxin of nitric oxide synthase in the rat mesentery: Lack of effect on action of vasoconstrictors. Br. J. Pharmacol. 1993; 109: 265–270.
23. Lee S., Son S.C., Han M.J. et al. Increased intestinal macromolecular permeability and urine nitrite excretion associated with liver cirrhosis with ascites. World J. Gastroenterol. 2008; 14(24): 3884–3890.
24. Schwartz D., Blantz R.C. Nitric oxide, sepsis and the kidney. Semin. Nephrol. 1999; 19(3): 272–276.
25. Such J., Hillebrand D.J., Guarner C. et al. Nitric oxide in ascitic fluid is an independent predictor of the development of renal impairment in patients with cirrhosis and spontaneous bacterial peritonitis. Eur. J. Gastroenterol. Hepatol. 2004; 16(6): 571–577.
26. Islas-Carbajal M.C., Covarrubias A., Grijalva G. et al. Nitric oxide synthases inhibition results in renal failure improvement in cirrhotic rats. Liver Int. 2005; 25(1): 131–140.
27. Moreau R., Lebrec D. Acute kidney injury: new concepts. Hepatorenal syndrome: the role of vasopressors. Nephron Physiol. 2008; 109(4): p73–p79.
28. Algahtani S.A., Fouad T.R., Lee S.S. Cirrhotic cardiomyopathy. Semin. Liver Dis. 2008; 28(1): 59–69.
29. Pozzi M., Carugo S., Boari G. et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26: 1131–1137.
30. Wong F., Siu S., Liu P. et al. Brain natriuretic peptide: Is it a predictor of cardiomyopathy in cirrhosis? Clin. Sci. (Lond.) 2001; 101: 621–628.
31. Pasqualetti P., Casale R. Plasma levels of arginine vasopressin in hepatorenal syndrome. Panminerva Med. 1998; 40(4): 294–298.
32. Leiva J.G., Salgado J.M., Estradas J. et al. Pathophysiology of ascites and dilutional hyponatriemia: contemporary use of aquaretic agents. Ann. Hepatol. 2007; 6(4): 214–221.
33. Ivarsen P., Frokiaer J., Aagaard N.K. et al. Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis. Gut. 2003; 52(8): 1194–1199.
34. Martin-Llahi M., Guevara M., Gines P. Hyponatremia in cirrhosis: clinical features and management. Gastroenterol. Clin. Biol. 2006; 30(10): 1144–1151.
35. Cardenas A., Gines P. Dilutional hyponatremia, hepatorenal syndrome and liver transplantation. Gastroenterol. Hepatol. 2008; 31(1): 29–36.
36. Schepke M. Hepatorenal syndrome: current diagnostic and therapeutic concepts. Nephrol. Dial. Transplant. 2007; 22 (Suppl. 8): 2–4.
37. Hecker R., Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956; 271: 1121–1125.
38. Sort P., Guevara M., Arroyo V. Hyperaldosteronism, spironolactone and liver cirrhosis. Gastroenterol. Hepatol. 1997; 20(3): 151–159.
39. Gotzberger M., Kaiser C., Landauer N. et al. Intrarenal resistance index for the assessment of early renal function impairment in patients with liver cirrhosis. Eur. J. Med. Res. 2008; 13(8): 383–387.
40. Garcia-Compean D., Blanc P., Larrey D. et al. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: A randomized controlled trial. Ann. Hepatol. 2002; 1: 29–35.
41. Wilson J.R. Dopamine in the hepatorenal syndrome. J.A.M.A. 1977; 238: 2719–2720.
42. Gines A., Salmeron J.M., Gines P. et al. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J. Hepatol. 1993; 17: 220–226.
43. Gluud L.L., Kjaer M.S., Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst. Rev. 2006; (4):CD005162.
44. Triantos C.K., Samonakis D., Thalheimer U. et al. Terlipressin therapy for renal failure in cirrhosis. Eur. J. Gastroenterol. Hepatol. 2009 [Epub ahead of print].
45. Gluud L.L., Christensen K., Christensen E. et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2009 [Epub ahead of print].
46. Nazar A., Pereira G.H., Guevara M. et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2009 [Epub ahead of print].
47. Duvoux C., Zanditenas D., Hezode C. et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology. 2002; 36(2): 374–380.
48. Angeli P., Volpin R., Gerunda G. et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690–1697.
49. Angeli P., Volpin R., Piovan D. et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology. 1998; 28: 937–943.
50. Assimakopoulos S.F., Thomopoulos K.C., Labropoulou-Karatza C. Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? World J. Gastroenterol. 2009; 15(25): 3194–3195.
51. Akriviadis E., Botla R., Briggs W. et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000; 119(6): 1637–1648.
52. De B.K., Gangopadhyay S., Dutta D. et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J. Gastroenterol. 2009; 15(13): 1613–1619.
53. Guevara M., Gines P., Bandi J.C. et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416–422.
54. Brensing K.A., Textor J., Perz J. et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288–295.
55. Alessandria C., Venon W.D., Marzano A. et al. Renal failure in cirrhotic patients: Role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur. J. Gastroenterol. Hepatol. 2002; 14: 1363–1368.
56. Wong F., Pantea L., Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55–64.
57. Linas S.L., Schaffer J.W., Moore E.E. et al. Peritoneovenous shunt in the management of the hepatorenal syndrome. Kidney Int. 1986; 30: 736–740.
58. Witzke O., Baumann M., Patschan D. et al. Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J. Gastroenterol. Hepatol. 2004; 19: 1369–1373.
59. Gonwa T.A., Mai M.L., Melton L.B. et al. Renal replacement therapy and orthotopic liver transplantation: The role of continuous veno-venous hemodialysis. Transplantation 2001; 71: 1424–1428.
60. Capling R.K., Bastani B. The clinical course of patients with type 1 hepatorenal yndrome maintained on hemodialysis. Ren. Fail. 2004; 26: 563–568.
61. Mitzner S.R., Stange J., Klammt S. et al. Improvement of hepatorenal syndrome with extracorporealalbumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 2000; 6: 277–286.
62. Gonwa T.A., Klintmalm G.B., Levy M. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59: 361–365.
63. Nair S., Verma S., Thuluvath P.J. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002; 35: 1179–1185.


Похожие статьи


Бионика Медиа